SATB1 and breast cancer: More recent studies are suggestive of adverse prognostic value for SATB1: significantly improved overall survival has been shown for homozygous SATB1 − 3600T/− 3363A/− 2984C haplotype carriers with expected lower SATB1 promoter activity in a cohort of breast cancer patients [24].